Advertisement

Topics

Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough

22:11 EDT 25 Oct 2017 | Drugs.com

REDWOOD CITY, Calif., October 26, 2017 /PRNewswire/ — Menlo Therapeutics Inc., a clinical stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) has initiated enrollment in a 170-subject Phase 2 trial...

Original Article: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough

NEXT ARTICLE

More From BioPortfolio on "Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough"

Advertisement
Quick Search
Advertisement
Advertisement